Critique of phase II agents for non-small cell lung cancer: what is our clinical need and which agents have potential?
1/5 보강
[INTRODUCTION] Phase II studies provide signals that guide therapeutic development for advanced NSCLC.
APA
Spagnuolo A, Spagnoletti I, et al. (2026). Critique of phase II agents for non-small cell lung cancer: what is our clinical need and which agents have potential?. Expert opinion on investigational drugs, 35(3), 239-251. https://doi.org/10.1080/13543784.2026.2636928
MLA
Spagnuolo A, et al.. "Critique of phase II agents for non-small cell lung cancer: what is our clinical need and which agents have potential?." Expert opinion on investigational drugs, vol. 35, no. 3, 2026, pp. 239-251.
PMID
41797519 ↗
Abstract 한글 요약
[INTRODUCTION] Phase II studies provide signals that guide therapeutic development for advanced NSCLC. This is particularly important for certain categories of patients, such as those who have already undergone immunotherapy and those with oncogene-addicted disease. However, promising results in phase II often do not translate into equally positive outcomes in phase III and the reason may be related to assay variability, sample heterogeneity, inadequate comparators or optimistic endpoints.
[AREAS COVERED] This paper provides an overview of treatments for advanced NSCLC and identifies settings where phase II evidence plays a decisive role: post-PD-(L)1/-chemotherapy, post-TKIs, frail patients or patients with brain disease. It also analyzes the reasons behind the failure of phase II success in phase III and proposes what makes a robust signal in phase II, while recognizing the limitations of surrogate endpoints. We take stock of the therapeutic classes that are gaining the most ground and provide a critical assessment of ongoing clinical programs.
[EXPERT OPINION] At present, a convincing phase II trial in NSCLC is possibly randomized, guided by biomarkers detected by standardized tests, with durable systemic and cerebral activity, inclusion of PROs, and is already in alignment with confirmatory study design and regulatory endpoints.
[AREAS COVERED] This paper provides an overview of treatments for advanced NSCLC and identifies settings where phase II evidence plays a decisive role: post-PD-(L)1/-chemotherapy, post-TKIs, frail patients or patients with brain disease. It also analyzes the reasons behind the failure of phase II success in phase III and proposes what makes a robust signal in phase II, while recognizing the limitations of surrogate endpoints. We take stock of the therapeutic classes that are gaining the most ground and provide a critical assessment of ongoing clinical programs.
[EXPERT OPINION] At present, a convincing phase II trial in NSCLC is possibly randomized, guided by biomarkers detected by standardized tests, with durable systemic and cerebral activity, inclusion of PROs, and is already in alignment with confirmatory study design and regulatory endpoints.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Carcinoma
- Non-Small-Cell Lung
- Clinical Trials
- Phase II as Topic
- Lung Neoplasms
- Antineoplastic Agents
- Drug Development
- Biomarkers
- Tumor
- Immunotherapy
- Animals
- Antibody-drug conjugates
- NSCLC
- biomarkers
- bispecific antibodies
- immunotherapy
- phase II trials
- surrogate endpoints
- tyrosine kinase inhibitors
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.